-transparent.png){kind=logo}
Two hundred and eight acceptable patients were treated with Yoshi 864 (2 mg/kg/day by iv push X 5 days repeated once every 6 weeks). Toxicity was minimal. There was an overall response rate of 11%. Cross resistance with other alkylating agents may not be present. Because of its lack of toxicity, Yoshi 864 should be further evaluated in chronic myelocytic leukemia, lymphomas, and carcinomas of the ovary and bladder where significant responses were seen. It should also be evaluated in combinations as a replacement for other alkylating agents which cause more nausea and vomiting.
Related Publications
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
April 1975,
Cancer,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
November 1976,
Cancer treatment reports,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
January 1978,
National Cancer Institute carcinogenesis technical report series,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
June 1972,
Cancer chemotherapy reports,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
September 1982,
Cancer treatment reports,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
February 1983,
Cancer treatment reports,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
May 1985,
Cancer treatment reports,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
September 1982,
Cancer treatment reports,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
February 2023,
Investigational new drugs,
S J Altman, and
G E Metter, and
T F Nealon, and
A J Weiss, and
G Ramirez, and
R E Madden, and
W S Fletcher, and
J G Strawitz, and
P M Multhauf
May 1973,
Cancer,
